F45 Training Holdings Inc. (FXLV)
OTCMKTS · Delayed Price · Currency is USD
0.0751
0.00 (0.00%)
Aug 1, 2025, 11:55 AM EDT
CTI BioPharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '23 Jun 30, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | 2018 |
| 81.95 | 104.42 | 125.22 | 82.31 | 92.69 | 57.76 | Upgrade | |
Revenue Growth (YoY) | -40.31% | -16.61% | 52.13% | -11.20% | 60.49% | 126.53% | Upgrade |
Cost of Revenue | 23.99 | 32.58 | 40.09 | 29.65 | 37.99 | 23.08 | Upgrade |
Gross Profit | 57.96 | 71.85 | 85.13 | 52.66 | 54.7 | 34.68 | Upgrade |
Selling, General & Admin | 161.58 | 186.38 | 178.41 | 57.83 | 41.13 | 15.43 | Upgrade |
Operating Expenses | 161.58 | 186.38 | 178.41 | 57.83 | 41.13 | 15.43 | Upgrade |
Operating Income | -103.62 | -114.53 | -93.28 | -5.16 | 13.58 | 19.25 | Upgrade |
Interest Expense | -22.45 | -14.98 | -59.35 | -9.4 | -0.41 | - | Upgrade |
Currency Exchange Gain (Loss) | 1.27 | 0.96 | 0.73 | 1.15 | -0.38 | -0.22 | Upgrade |
Other Non Operating Income (Expenses) | -3.36 | - | -48.6 | -8.82 | - | - | Upgrade |
EBT Excluding Unusual Items | -128.16 | -128.55 | -200.51 | -22.23 | 12.78 | 19.03 | Upgrade |
Asset Writedown | -32.35 | -32.35 | -2.5 | - | - | - | Upgrade |
Other Unusual Items | 3.19 | 4.46 | - | - | -22.26 | - | Upgrade |
Pretax Income | -157.32 | -156.44 | -203.01 | -22.23 | -9.49 | 19.03 | Upgrade |
Income Tax Expense | 1.89 | 22.36 | -9.54 | 3.06 | 3.12 | 6.24 | Upgrade |
Net Income | -159.2 | -178.8 | -193.47 | -25.29 | -12.6 | 12.79 | Upgrade |
Net Income to Common | -159.2 | -178.8 | -193.47 | -25.29 | -12.6 | 12.79 | Upgrade |
Net Income Growth | - | - | - | - | - | 21955.17% | Upgrade |
Shares Outstanding (Basic) | 97 | 96 | 60 | 50 | 58 | 58 | Upgrade |
Shares Outstanding (Diluted) | 97 | 96 | 60 | 50 | 58 | 58 | Upgrade |
Shares Change (YoY) | 3.74% | 60.09% | 19.35% | -13.04% | - | - | Upgrade |
EPS (Basic) | -1.64 | -1.86 | -3.21 | -0.50 | -0.22 | 0.22 | Upgrade |
EPS (Diluted) | -1.64 | -1.86 | -3.21 | -0.50 | -0.22 | 0.22 | Upgrade |
EPS Growth | - | - | - | - | - | 21955.10% | Upgrade |
Free Cash Flow | -55.47 | -104.55 | -66.51 | -20.29 | 7.83 | 9.12 | Upgrade |
Free Cash Flow Per Share | -0.57 | -1.08 | -1.10 | -0.40 | 0.14 | 0.16 | Upgrade |
Gross Margin | 70.72% | 68.81% | 67.98% | 63.98% | 59.02% | 60.05% | Upgrade |
Operating Margin | -126.44% | -109.68% | -74.49% | -6.27% | 14.65% | 33.33% | Upgrade |
Profit Margin | -194.27% | -171.23% | -154.50% | -30.72% | -13.60% | 22.15% | Upgrade |
Free Cash Flow Margin | -67.68% | -100.12% | -53.12% | -24.65% | 8.44% | 15.78% | Upgrade |
EBITDA | -98.37 | -108.6 | -90.13 | -4.77 | 13.8 | 19.56 | Upgrade |
EBITDA Margin | -120.04% | -103.99% | -71.98% | -5.80% | 14.89% | 33.87% | Upgrade |
D&A For EBITDA | 5.25 | 5.93 | 3.15 | 0.39 | 0.22 | 0.31 | Upgrade |
EBIT | -103.62 | -114.53 | -93.28 | -5.16 | 13.58 | 19.25 | Upgrade |
EBIT Margin | -126.44% | -109.68% | -74.49% | -6.27% | 14.65% | 33.33% | Upgrade |
Effective Tax Rate | - | - | - | - | - | 32.78% | Upgrade |
Revenue as Reported | 81.95 | 104.42 | 125.22 | 82.31 | 92.69 | 57.76 | Upgrade |
Updated Nov 7, 2023. Source: S&P Global Market Intelligence. Standard template. Financial Sources.